Gram-positive bacteria specific binding compounds
US-2015376266-A1 · Dec 31, 2015 · US
Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof
US9458227B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9458227-B2 |
| Application number | US-201414548173-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 19, 2014 |
| Priority date | Apr 21, 2004 |
| Publication date | Oct 4, 2016 |
| Grant date | Oct 4, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli . Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli . Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.
First claim
Opening claim text (preview).
What is claimed is: 1. An antibody comprising the amino acid sequences of SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:9, and having a non-IgG2 constant region. 2. The antibody of claim 1 , wherein the antibody has an IgG1 constant region. 3. The antibody of claim 1 , wherein the antibody comprises the amino acid sequence of SEQ ID NO:1. 4. The antibody of claim 1 , wherein the antibody comprises the amino acid sequences of SEQ ID NO:10, SEQ ID NO:11 and SEQ ID NO:12. 5. The antibody of claim 1 , wherein the antibody comprises the amino acid sequence of SEQ ID NO:2. 6. The antibody of claim 1 , wherein the antibody is isolated. 7. The antibody of claim 1 , wherein the antibody is a monoclonal antibody. 8. A pharmaceutical composition comprising the antibody of claim 1 . 9. An antigen-binding antibody fragment of the antibody of claim 1 , wherein the fragment comprises amino acid sequence of the constant region. 10. A pharmaceutical composition comprising the antigen-binding antibody fragment of claim 9 . 11. A method of treating a subject having or at risk of developing an infection by a bacterial strain expressing PNAG comprising administering to a subject in need of such treatment an antibody of claim 1 in an effective amount. 12. A method of treating a subject having or at risk of developing an infection by a bacterial strain expressing PNAG comprising administering to a subject in need of such treatment an antigen-binding antibody fragment of claim 9 in an effective amount.
Assignees
Inventors
Classifications
Antibacterial agents · CPC title
Immunostimulants · CPC title
- C07K16/12Primary
against material from bacteria · CPC title
Complementarity determining region [CDR] · CPC title
comprising antibodies · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9458227B2 cover?
- The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG suc…
- Who is the assignee on this patent?
- Brigham & Womens Hospital Inc, Beth Israel Deaconess Medical Ct Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/12. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 04 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).